Summary table
| Drug | Paper | Concentration studied | Diluents | Devices | Temperature | API limits | Duration | Additional comments |
| Amoxicillin7 24 | Binson et al | 6 g in 48 mL | Water for injection | Baxter SV infuser | 37°C | 90%–110% | Within 2 hours | Not suitable for continuous infusion Impact of buffering not investigated |
| Fawaz et al | 1000 mg in 70 mL (co-amoxiclav 1.2 g in 70 mL) | Glucose 5% Sodium chloride 0.9% Water for injection | Glass vials | 37°C | 90%–110% | 3.5–4.5 hours | ||
| Ampicillin8 | Nakamura et al | 12 g in 240 mL | Sodium chloride 0.9% | Baxter LV10 | 31.1°C | 90%–110% | Within 5 hours | Not suitable for continuous infusion Impact of buffering not investigated |
| Benzylpenicillin8 | Nakamura et al | 14.4 g in 240 mL | Acetate Ringers solution | Baxter LV10 | 31.1°C | 90%–110% | 24 hours | Potential for extended stability using buffer Candidate for YCD-compliant stability studies |
| Cefazolin9 10 | Metsu et al | 1 g in 1000 mL | Sodium chloride 0.9% | Ecoflac infusion bags | 35°C | 90%–110% | 48 hours | Potential for extended stability using buffer Candidate for YCD-compliant stability studies |
| Akahane et al | 6 g in 240 mL | Glucose 5% Sodium chloride 0.9% | Baxter LV10 | 31.1°C | 90%–110% | At least 24 hours | ||
| Cefepime11 | Ressault et al | 1 g in 50 mL | Sodium chloride 0.9% | Unspecified | 33°C | 90%–110% | Up to 12 hours | Insufficient data to support continuous infusion currently; studies to evaluate stability and degradants required. |
| Cefmetazole9 | Akahane et al | 8 g in 240 mL | Glucose 5% Sodium chloride 0.9% | Baxter LV10 | 31.1°C | 90%–110% | At least 24 hours | Insufficient data to support continuous infusion currently; studies to evaluate stability and degradants required |
| Ceftaroline12 | Al Madfai et al | 300 mg in 50 mL | Glucose 5% Sodium chloride 0.9% | Baxter LV10 | 35°C | 95%–105% | Up to 6 hours | Data in elastomeric infusers do not support infusions longer than 6 hours |
| Ceftolozane–tazobactam13 | Raby et al | 300–6000 mg in 240 mL | Sodium chloride 0.9% | Baxter LV10 | 37°C | 90%–110% | 24 hours | For additional information, also see Jamieson et al 20 |
| Doripenem9 | Akahane et al | 3 g in 240 mL | Acetate Ringers solution | Baxter LV10 | 31.1°C | 90%–110% | At least 8 hours | Insufficient data to support continuous infusion currently; studies to evaluate stability and degradants required |
| Meropenem9 14–16 | Jamieson et al | 1–2 g in 48 mL | Sodium chloride 0.9% | Baxter LV10 | 32°C | 95%–105% | Within 6 hours | Data in elastomeric infusers do not support infusions longer than 6 hours. |
| Fawaz et al | 2 g in 140 mL | Sodium chloride 0.9% | Infusion bags | 33°C | 90%–110% | Within 5 hours | Data in elastomeric infusers do not support infusions longer than 6 hours | |
| Delattre et al | 1–2 g in 48 mL | Sodium chloride 0.9% | Syringes | 37°C | 90%–110% | Within 3 hours | ||
| Akahane et al | 3 g in 240 mL | Sodium chloride 0.9% | Baxter LV10 | 31.1°C | 90%–110% | Within 5–6 hours | ||
| Piperacillin–tazobactam9 10 | Metsu et al | 24 and 48 g in 1000 mL | Sodium chloride 0.9% | Ecoflac infusion bags | 35°C | 90%–110% | 48 hours | For additional information, also see Jamieson et al 20 |
| Akahane et al | 18 g in 240 mL | Glucose 5% Sodium chloride 0.9% | Baxter LV10 | 31.1°C | 90%–110% | At least 24 hours | ||
| Voriconazole17 | Harmanjeet et al | 200 mg in 100 mL | Glucose 5% Sodium chloride 0.9% | Baxter SV50 | 35°C | 95%–105% | At least 4 hours | Potential for longer stability however unsure of clinical need |
API, active pharmaceutical ingredient; YCD, Yellow Cover Document.